Back to School: How biopharma can reboot drug development. Access exclusive analysis here


WASHINGTON - Declaring that increasing competition has caused the U.S. leadership in biotechnology to diminish, the Clinton administration last week sent to Congress details of a $4.3 billion "Federal Biotechnology Research Initiative" whose goal is to "sustain and extend U.S. leadership in biotechnology research for the 21st century."

The proposal is nearly 7 percent above the $4 billion initially proposed last year by President Bush's biotech initiative. However,

Read the full 677 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers